Vitreous Level Of Tumor Necrosis Factor Alpha In Patients With Retinal Vein Occlusion

NCT05532475 | Completed

• 1 other identifier: MS-654-2021
• Study Type: observational
• Target: 40
• Locations: 1 country
• Sites: 1

Brief Summary

To assess the levels of TNF- α in vitreous samples of patients with retinal vein occlusion prior to administration of intravitreal anti-VEGF and compare them to levels in vitreous samples of normal subjects so as to investigate the association of vitreous tumor necrosis factor with the pathogenesis of retinal vein occlusion.

Conditions

Retinal Vein Occlusion

Keywords

Tumor necrosis factor alpha

Outcome Measures

Primary Outcomes (1)

• to assess vitreous level of tumor necrosis factor alpha in retinal vein occlusion and compare it to patient undergoing cataract surgery

  Day 1

Study Arms (2)

cases

patient with retinal vein occlusion

Diagnostic Test: measurement of vitreous level of tumor necrosis factor alpha

control

cataract patient undergoing cataract surgery

Diagnostic Test: measurement of vitreous level of tumor necrosis factor alpha

Interventions

measurement of vitreous level of tumor necrosis factor alpha DIAGNOSTIC_TEST

measurement of vitreous level of tumor necrosis factor alpha using ELISA technique

cases; control

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Retinal venous occlusion patients admitted in KasrAlainy Hospital for Intravitreal Injection of Lucentis (Cases) compared to patient without retinal vein occlusion admitted for cataract surgery (Controls).

You may qualify if:

• Any patient with retinal vein occlusion not older than 6 months with no history of Anti-VEGF injection

You may not qualify if:

• Diabetic patients.
• Other causes of retinal vascular diseases.
• Patients with history of treatment of retinal vein occlusion.
• Previous intraocular surgery except cataract surgery performed 6 months before the study.
• Subjects with severe systemic inflammatory diseases
• Retinal vein occlusion secondary to retinal vasculitis.
• All retinal pathologies.
• Patients receiving Systemic steroids or Immunosuppressive therapy.

Sponsors & Collaborators

• Kasr El Aini Hospital: lead

Study Sites (1)

Kasr ALainy University hospital

Cairo, 12916, Egypt

Location

MeSH Terms

Conditions

Retinal Vein Occlusion

Condition Hierarchy (Ancestors)

Retinal Diseases; Eye Diseases; Venous Thrombosis; Thrombosis; Embolism and Thrombosis; Vascular Diseases; Cardiovascular Diseases

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Lecturer of ophthalmology- faculty of medicine- Cairo University

Study Record Dates

• First Submitted: September 3, 2022
• First Posted: September 8, 2022
• Study Start: March 12, 2022
• Primary Completion: October 20, 2022
• Study Completion: October 30, 2022
• Last Updated: November 27, 2024

Record last verified: 2024-11

Data Sharing

• IPD Sharing: Will not share

Locations

EG (1)